Table 3 Change in clinical characteristics, left ventricular function and cardiopulmonary capacity compared with baseline 7 days and 3 months after initiation of cardiac resynchronisation therapy.
| Characteristics | Optimal LV lead position (n = 25) | Non‐optimal LV lead position (n = 22) | p Value |
|---|---|---|---|
| ΔNYHA functional class at 3 months | 1.3 (0.8) | 1.0 (0.7) | 0.2 |
| ΔQRS duration at 3 months (ms) | 44 (16) | 34 (21) | 0.155 |
| ΔLVEF at 7 days (%) | 7 (2) | 4 (3) | <0.001 |
| ΔLVEF at 3 months (%) | 9 (2) | 5 (3) | <0.001 |
| ΔLVGS at 7 days (%) | 2.8 (1.3) | 1.6 (1.2) | 0.009 |
| ΔLVGS at 3 months (%) | 3.1 (1.5) | 2.5 (1.5) | 0.012 |
| ΔVo2max at 3 months (ml/kg/min) | 2.0 (0.8) | 1.1 (0.5) | 0.001 |
Results are shown as mean (SD).
LVEF, left ventricular ejection fraction; LVGS, left ventricular global strain; NYHA, New York Heart Association; Vo2max, oxygen consumption at peak exercise.